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Abstract
Purpose In lung cancer patients with multiple lesions, the
differentiation between metastases and second primary
tumours has significant therapeutic and prognostic implica-
tions. The aim of this retrospective study was to investigate
the potential of
18F-FDG PET to discriminate metastatic
disease from second primary lung tumours.
Methods Of 1,396 patients evaluated by the thoracic
oncology group between January 2004 and April 2009 at
the Radboud University Nijmegen Medical Centre, patients
with a synchronous second primary lung cancer were
selected. Patients with metastatic disease involving the
lungs served as the control group. Maximum standardized
uptake values (SUVs) measured with
18F-FDG PET were
determined for two tumours in each patient. The relative
difference between the SUVs of these tumours (ΔSUV) was
determined and compared between the second primary
group and metastatic disease group. Receiver-operating
characteristic (ROC) curve analysis was performed to
determine the sensitivity and specificity of the ΔSUV for
an optimal cut-off value.
Results A total of 37 patients (21 metastatic disease, 16
second primary cancer) were included for analysis. The
ΔSUV was significantly higher in patients with second
primary cancer than in those with metastatic disease (58 vs
28%, respectively, p<0.001). The area under the ROC
curve was 0.81 and the odds ratio for the optimal cut-off
was 18.4.
Conclusion SUVs from
18F-FDG PET images can be
helpful in differentiating metastatic disease from second
primary tumours in patients with synchronous pulmonary
lesions. Further studies are warranted to confirm the
consistency of these results.
Keywords FDG PET.Second primary tumour.Metastatic
disease.Lung cancer.Standardized uptake value.CT
Introduction
Lung cancer is the leading cause of cancer-related mortality
[1]. Although the incidence of lung cancer is decreasing [1],
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DOI 10.1007/s00259-010-1505-2the number of patients presenting with a second primary
cancer has dramatically increased in the last decades [2,
3]. A simultaneous second primary lung carcinoma occurs
in 1–8% of lung cancer patients [4, 5] .T h eo c c u r r e n c eo f
multiple primary cancers may be attributed to shared
aetiological factors [3, 6]. Specifically, 70% of second
primary cancers presenting in lung cancer patients are
tobacco related, the most common locations including the
upper aerodigestive tract, the uroepithelium and the
colorectum [7].
Second primary cancers can be divided into synchronous
cancers, occurring simultaneously with the index tumour,
and metachronous cancers, presenting more than 6 months
after the index tumour [8].
F o rl u n gc a n c e rp a t i e n t s
18F-fluorodeoxyglucose
positron emission tomography (FDG PET) is recommen-
ded according to the American College of Chest Physi-
cians (ACCP) guidelines as standard work-up in
potentially curable lung cancer based on conventional
imaging. The rate of detection of unanticipated metastasis
by FDG PET has been reported as 1–18% in patients with
clinical stage I or II disease [9]. When an FDG PET scan
is made for lung cancer staging, both metastases as well
as synchronous primary tumours can be visualized. While
multiple lung nodules of varying sizes are usually
classified as metastases, it is a much greater challenge to
distinguish a lung metastasis from a second primary lung
carcinoma when only one additional pulmonary lesion is
detected [10].
Discriminating metastatic disease from second primary
lung cancer is of great clinical interest because it has large
therapeutic and prognostic implications. Metastatic lung
cancer is considered incurable and is treated with palliative
intent [1]. The survival of lung cancer patients presenting
with multiple primary cancers has been found to be similar
compared to patients with solitary primary lung cancer [7,
11], and an aggressive surgical approach has proven to be
safe and justified in patients with synchronous multiple
primary lung cancers and node-negative disease [12].
Therefore, multiple primary cancers should be staged
separately and—in cases of early stage—treated with
curative intent, including surgery when the tumours are
resectable.
Obviously, when two tumours are histologically
different they are easily recognized as separate primary
tumours. However, when tumours share common histo-
logical features, it remains uncertain whether they should
be classified as metastases or separate primary tumours.
Immunohistochemistry and TP53 gene mutation analyses
may be used to ascertain the clonality of synchronous
tumours. The latter has been promoted as a gold standard
for differentiation of second primary tumours from
metastatic disease [13–15].
FDG uptake reflects metabolic activity of tumour lesions,
which depends on a variety of tumour characteristics, such as
degree of proliferation, hypoxia and tumour aggressiveness.
FDG uptake can be quantified by calculating standardized
uptake values (SUVs) on PET images. SUVs have been
reported to correlate with histological subtypes and tumour
stage [16–18] and have been shown to increase with poorer
tumour differentiation [16, 19], a higher proportion of
actively proliferating cells [19] and increased aggressiveness
of the tumour [20].
Since tumours with a shared clonal origin often
behave similarly and have common histological features,
we hypothesized that the SUVs of clonally related
tumours (i.e. metastases) would be more similar than
those of tumours with a different clonal origin. Conse-
quently, we hypothesized that the SUVs of metastases
approach the SUV of the primary tumour they originate
from and that the SUVs of two primary tumours differ to
a greater extent.
This retrospective study evaluated the potential of SUVs
measured with FDG PET for the characterization of
synchronous pulmonary lesions.
Materials and methods
Patients
A total of 1,396 patients (536 women and 860 men) who
had been evaluated by the multidisciplinary thoracic
oncology group between January 2004 and April 2009 at
the Radboud University Nijmegen Medical Centre were
retrospectively screened. First, patients were included in the
‘second primary group’ when they presented with two
primary tumours, including any index tumour and a
synchronous pulmonary tumour, defined as a tumour
diagnosed within 6 months of diagnosis of the index
tumour [8]. Second, patients with lung cancer metastasized
to the same lobe (stage IIIB) or to different lobes or other
organs (stage IV) and patients with a primary cancer
elsewhere in the body metastasized to the lungs (stage IV)
were consecutively searched for and included to form the
control group (or ‘metastatic disease group’), until a similar
sample size as of the second primary group was reached.
Patients with any cancer-related treatment prior to FDG
PET were excluded from the study. In all patients, a
diagnostic contrast-enhanced chest computed tomography
(CT) scan was performed including CT scan of liver and
adrenal glands prior to or directly following the FDG PET.
An overview of the inclusion and exclusion criteria is
presented in the flow chart of Fig. 1.
A tumour was considered a second primary tumour
when histopathological or immunohistochemical features
2038 Eur J Nucl Med Mol Imaging (2010) 37:2037–2047differed from those of the index tumour. In cases of
tumours with identical histological and immunohisto-
chemical features, TP53 mutation analysis had to be
performed demonstrating different clonal origins of the
tumours. Patients without conclusive diagnosis of
second primary cancer due to impossibility of gaining
adequate tissue samples were excluded. Metastatic
disease was concluded based on identical histopatho-
logical findings of multiple lesions. Additionally,
tumours were considered metastases when multiple
(more than two) tumours in a pattern typical for
metastatic spread of the identified primary tumour had
been localized on imaging modalities.
When FDG uptake is measured in small tumours, bias
can be introduced by the partial volume effect resulting in
underestimation of the tumour SUV [21]. To prevent bias
by partial volume effects, patients with a tumour smaller
than 15 mm were excluded from analysis.
Data on patient and tumour characteristics were
extracted from patient charts and histopathology reports.
18F-FDG PET data acquisition and reconstruction
All patients underwent whole-body FDG PET as part of
their routine preoperative staging procedure. Prior to FDG
injection, patients fasted for at least 6 h. Intake of sugar-free
liquids was permitted. Immediately prior to the procedure,
patients were hydrated with 500 ml of water and 60 min
after intravenous injection of approximately 250 MBq FDG
(Covidien, Petten, The Netherlands) and 10 mg furosemide,
images of the area between the proximal femora and the
base of the skull were acquired.
Scans were acquired with a hybrid PET/CT scanner
(Biograph Duo, Siemens Medical Solutions USA, Inc.,
Knoxville, TN, USA) containing a two-slice CT scanner. A
low-dose CT scan for localization and attenuation correc-
tion purposes was acquired in the caudocranial direction.
Scanning parameters included 40 mA s (50 mA s for patient
weight >100 kg and 60 mA s for >120 kg), 130 kV, 5-mm
slice collimation, 0.8-s rotation time and pitch of 1.5,
reconstructed to 3-mm slices for smooth coronal represen-
Fig. 1 Flowchartoftheincluded
and excluded patients
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expiration breath-hold. No intravenous contrast was ap-
plied. For PET, a three-dimensional whole-body emission
scan was acquired during free breathing; the acquisition
time per bed position was 4 min for emission only. All
images were iteratively reconstructed using 2 iterations and
8 subsets and a 5-mm 3-D Gaussian filter, resulting in an
effective spatial resolution of 5 mm full-width at half-
maximum (FWHM).
Standardized uptake values
The maximum SUV [SUVmax, the activity from the
maximum-valued pixel within the tumour volume of
interest (VOI); hereafter referred to as SUV] normalized
to injected activity and patient body weight was calculated
at approximately 60 min after tracer injection for each
primary lesion and the chosen metastatic lesion with use of
the following equation: SUV = maximum activity concen-
tration in the VOI [kBq/ml]/(injected dose [MBq/ml]/
patient body weight [kg]). In patients with multiple
metastatic lesions, the lesion with the largest diameter was
chosen to prevent partial volume effects. Subsequently, the
relative difference between the SUV of the index tumour
and the SUV of the synchronous tumour (the second
primary tumour or metastatic lesion) was assessed
(ΔSUV) and expressed in percentages of the highest SUV.
Examples of deduction of the ΔSUV from the SUVs of two
tumours are given in Figs. 2 and 3. Image analyses were
performed on the Inveon Research Workplace version 2.2
(IRW, Siemens/CT, Knoxville, TN, USA).
Area under the receiver-operating characteristic curve
and cut-off value
After constructing a receiver-operating characteristic (ROC)
curve of the ΔSUV, the area under the curve (AUC) was
assessed, and the sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) and odds ratio
(OR) were determined for an optimal cut-off of the ΔSUV.
Chest CT
In all patients, a diagnostic contrast-enhanced chest CTscan
was performed. For each patient, CT tumour characteristics
were assessed by a radiologist. Morphological features of
pulmonary nodules suspicious for a primary cancer were
speculation, cavitation, irregular margins and pleural or
bronchial traction. Tumours were considered metastases if
the following features were present: round lesions, sharp
borders and homogeneous. In cases of more than two
pulmonary nodules the same nodules used for the FDG
PET evaluation were chosen.
Statistical analyses
Since the ΔSUV was not normally distributed in both
groups (Shapiro-Wilk test, p<0.05), an independent sam-
ples one-tailed Mann-Whitney U test was used to compare
the mean ΔSUV between the second primary tumour and
metastatic disease group. Mean age and number of pack
years were compared using a two-sided t test. A chi-square
test was used to compare the proportions of smokers
between the groups. The level of significance was set at
0.05 for all analyses.
Results
Patient characteristics
A total of 54 eligible patients with synchronous malignan-
cies (32 metastatic disease and 22 second primary cancer,
respectively) were included. After exclusion of patients for
whom the digital PET data were unavailable (n=3), and
after exclusion of patients with lesions <15 mm (n=14), 37
patients remained for analysis. Of those patients, 21 were
diagnosed with metastatic disease and 16 with two primary
tumours (Fig. 1).
The mean age of the patients (23 men and 14
women) was 68 years (range: 47–85 years). Other
patient characteristics, including smoking status, are
presented in Table 1. Patient age, sex and smoking status
were not significantly different between patients with
metastatic disease and a second primary tumour (p>
0.05).
Sites of the index tumour in patients with second
primary lung cancer were the lung (n=7), the color-
ectum (n=5) and the head and neck (n=4). Of 16 second
primary cancer patients, 12 (75%) had two tumours of
early stage (stage I–IIIA) and were considered potentially
curable.
In the majority of cases (76%), metastatic disease was
diagnosed based on the clinical pattern (multiple lesions
spread in a manner consistent with metastatic pulmonary
cancer). The diagnosis of second primary cancer was
primarily (81%)—as can be expected—based on histopath-
ological differences. Only in three cases was further
immunohistochemistry (two patients) or TP53 mutation
(one patient) analysis required for a definite conclusion.
Tumour characteristics
Tumour characteristics are presented in Table 1.A l l
tumours were carcinomas, except for one tumour in the
second primary group which was classified as a mesothe-
lioma. Adenocarcinomas were the most commonly diag-
2040 Eur J Nucl Med Mol Imaging (2010) 37:2037–2047nosed tumours in both groups. Differentiation of the
tumours was better in the second primary group than in
the metastatic disease group, although in both groups
tumours were most frequently poorly differentiated.
Relative differences between standardized uptake values
The mean intra-individual ΔSUV between lesions was
significantly higher in patients with a second primary
tumour [58%, 95% confidence interval (CI): 46–70%] as
compared to those with metastatic disease (28%, 95% CI:
19–37%) (p<0.001). Figure 4 shows box and whisker plots
of the ΔSUV for both groups. Although the ranges of the
groups show overlap, the majority (75%) of patients with
metastatic disease has a ΔSUV below 39%, whereas the
ΔSUV exceeds 46% for the majority of the second primary
group (Fig. 4). The individual patient data on SUVmax and
ΔSUV for the metastasis and second primary group are
outlined in Tables 2 and 3.
Area under the ROC and cut-off value
The AUC for ΔSUV was 0.81 (95% CI: 0.67–0.96, p=
0.001) to predict a second primary tumour (Fig. 5), which
represents a moderately high discriminative ability of the
ΔSUV [22]. The left upper corner of the ROC curve was
chosen as the optimal cut-off, which corresponds with a
ΔSUV of 41%. This cut-off was associated with a
Fig. 2 FDG PET of a patient
with two primary lung tumours.
FDG PET demonstrating a
moderately differentiated
adenocarcinoma (a) in the left
upper lobe with an SUV of 12.1
and a synchronous second
primary with similar histology
but a different clonal origin
demonstrated by TP53 mutation
analysis (b) in the right lower
lobe with an SUV of 3.5. The
ΔSUV between the SUVs of the
two primary tumours was
12:1   3:5 ðÞ =12:1»100% ¼
71%
Fig. 3 FDG PET of a patient with metastasized lung cancer (stage IV).
FDG PET demonstrating a primary well-differentiated adenocarcinoma
located in the right upper lobe of the lung with an SUV of 22.3 and a
metastaticlesion in theright middle lobe ofthelung withan SUVof23.1.
The ΔSUV in this patient was 23:1   22:3 ðÞ =23:1»100% ¼ 3%
Eur J Nucl Med Mol Imaging (2010) 37:2037–2047 2041sensitivity, specificity, PPV, NPV and OR of 81, 81, 76, 85
and 18.4%, respectively.
Chest CT
Individual data of CTcharacteristics are outlined in Table 4.
Of 21 patients in the metastasis group, 19 (90%) had at
least one tumour containing morphological features of a
metastasis. In the second primary group, a definite
diagnosis based on CT morphological features could be
made in only eight patients (50%). Of these, three patients
had a tumour suspicious for a metastasis, and five patients
had two tumours both suspected of being a second primary
tumour.
Second primary
group (n=16)
Metastatic
disease group
(n=21)
Patient characteristics p value
Mean age
(range)
68 years
(49–85 years)
67 years (47–
84 years)
0.715
Sex (m:v) 11:5 12:9 0.471
Smoking
status
Smoker 7 10 0.713
Ex-smoker 7 9
Non-smoker 2 1
Missing 0 1
Mean no. of
pack years
33.6±15.9 35.0±21.2 0.842
Conclusion
a
based on
Histopathology 13 5
P53 mutation analysis 1 0
Immunohistochemistry 2 0
Clinical features 0 16
Curability
b Potentially curable 12 0
Incurable 4 21
Characteristics
of primary
tumours
Index
tumour
Synchronous
pulmonary
tumour
Site Lung 7 16 21
Colorectum 5 0 0
Head and neck 4 0 0
Histopathology SCLC 0 0 3
NSCLC AC 9 9 13
BAC 0 1 0
SCC 7 2 1
LCC 0 2 2
Undifferentiated 0 0 2
Other 0 2 0
Differentiation Very poor 0 0 3
Poor 6 8 7
Intermediate 8 2 1
Well 0 2 1
Unspecified 2 4 9
Stage
c IA 4 5 0
IB 2 1 0
IIA 2 2 0
IIB 2 3 0
IIIA 4 2 0
IIIB 0 1 2
IV 2 1 19
Missing 0 1 0
Table 1 Patient and primary
tumour characteristics
SCLC small cell lung carcino-
ma, NSCLC non-small cell lung
carcinoma, AC adenocarcinoma,
BAC bronchioloalveolar carci-
noma, SCC squamous cell car-
cinoma, LCC large cell
carcinoma
aThe conclusion second primary
tumour or metastatic disease
was based on histopathological
or immunohistochemical
features, TP53 mutation
analysis results or clinical
features. The latter included
localization of multiple (more
than two) malignancies in a
pattern typical for
metastatic spread of the
identified primary tumour
bPatients with two tumours of
stage I–IIIAwere considered
potentially curable, whereas
patients with at least one
tumour staged IIIB/IV were
considered incurable (TNM
staging system version 6)
cAccording to the sixth edition
of the TNM classification for
lung cancer developed by
the International Association
for the Study of Lung
Cancer [42]
2042 Eur J Nucl Med Mol Imaging (2010) 37:2037–2047Discussion
To our knowledge, this is the first study investigating the
role of quantitative FDG PET in discriminating metastases
from second primary tumours in cases of synchronously
presenting lesions. A significantly larger ΔSUV between
two tumours was found in patients presenting with two
primary tumours as compared to patients with metastatic
disease involving the lungs. The moderately high accuracy,
as measured with the AUC, as well as the good sensitivity
and specificity of the ΔSUV support the use of FDG PETas
a modality for discriminating second primary lung tumours
from metastases. The OR for the optimal cut-off of 41%
was 18.4, indicating that the odds of a second primary
tumour was 18.4 times higher in patients with a ΔSUV>
41% than in those with a ΔSUV<41%. Most patients with
second primary cancer (75%) had two early stage tumours
(I–IIIA), meaning they were potentially curable.
A definite diagnosis of metastatic disease or second
primary tumour based on CT scan characteristics could be
made in 90% of patients with metastases and in only eight
patients (50%) with second primary cancer. Furthermore, in
only five of eight patients was the diagnosis right.
Previously, multiple case reports and studies have been
published presenting cases of unexpected synchronous
primary lung tumours detected by FDG PET [23–26]. On
Values Metastatic  disease 
group (n=21) 
Second primary 
group (n=16) 
Lowest value within Q1 - 1.5 IQR (a)  2 18 
25% percentile (Q1)  14 46 
Median (50% percentile) (M)  26 69 
75% percentile (Q3)   39 73 
Interquartile range (IQR)  25 27 
Highest value within Q3 + 1.5 IQR (b)  76.5 87 
Outlier (o)  77 
Fig. 4 Box and whisker plots showing the distribution of the ΔSUV
for both groups. Q1 first quartile, M median, Q3 third quartile, IQR
interquartile range
Patient no. Location
tumour 1
SUVmax
tumour 1
Location
tumour 2
SUVmax
tumour 2
ΔSUV
a ΔSUV%
b
1 Lung, left hilum 7.90 Left 5th rib 7.30 0.60 8
2 Lung, RUL 6.30 Lung, RUL 4.30 2.00 32
3 Lung, RUL 16.2 Liver 14.3 1.90 12
4 Lung, LLL 8.00 Larynx 9.30 1.30 14
5 Lung, right hilum 18.2 Lung, left 24.6 6.40 26
6 Lung, RML 34.8 Th 12 26.6 10.2 29
7 Lung, RLL 27.6 Lung, LUL 13.4 14.2 51
8 Lung, RLL 2.50 Lung, RLL 2.20 0.30 12
9 Lung, LLL 10.5 Left iliac bone 10.7 0.20 2
10 Lung, RUL 5.90 Lung, right hilum 3.60 2.30 29
11 Lung, LUL 16.5 Right 6th rib 4.10 12.4 75
12 Lung, RUL 22.3 Lung, RML 23.1 0.80 3
13 Lung, RUL 6.20 Th 11 4.90 1.30 21
14 Lung, right 12.4 Lung, LUL 7.10 5.30 43
15 Lung, RUL 9.60 Right adrenal gland 5.70 3.90 41
16 Lung, RUL 13.2 Right iliac crest 3.00 10.2 77
17 Lung, RLL 7.20 Right 5th rib 5.30 1.90 26
18 Lung, RML 12.5 Lung, RLL 16.4 3.90 24
19 Lung, RUL 13.5 Right PSIS 11.4 2.10 16
20 Lung, RLL 5.40 L1 6.40 1.00 16
21 Lung, RML 5.90 Lung, RML 4.10 1.80 31
Mean ± SD 4.00±4.22 28±21
Table 2 Individual results of
metastasis group
SUVmax maximum standardized
uptake value, RUL right upper
lobe, RLL right lower lobe, LUL
left upper lobe, RML right
middle lobe, LLL left lower
lobe, Th thoracic vertebra, L
lumbar vertebra, PSIS posterior
superior iliac spine, SD standard
deviation of the mean
aThe absolute difference
between the SUVmax of tumour
1 and SUVmax of tumour 2
bThe relative difference
between the SUVmax of tumour
1 and the SUVmax of tumour
2, expressed in percentages of
the highest SUVmax
Eur J Nucl Med Mol Imaging (2010) 37:2037–2047 2043the contrary, only few reports exist in which FDG PET
contributes in determining the clonal origin of synchronous
tumours [27, 28]. The current available literature further
supports our hypothesis that SUVs can differentiate
tumours of common origin and with common biological
behaviour (i.e. metastases) from those of separate clonal
origin (i.e. multiple primary tumours). That is, FDG uptake
has been reported to relate to several tumour characteristics,
including histological subtype [16–19, 29] and tumour
aggressiveness [16, 19, 20].
FDG PET imaging is already extensively being used in
patients with lung cancer for several purposes, including the
diagnosis of recurrent disease, staging, prognostic stratifi-
cation and radiotherapy planning [30–33]. Also, it has been
shown to be an accurate modality to differentiate benign
from malignant solitary pulmonary lesions [30, 34].
Furthermore, FDG PETcan be used to monitor the response
of non-small cell lung cancer to chemotherapy [35],
radiotherapy and potentially to targeting of cell signalling
pathways [36]. The results presented implicate that the use
of FDG PET might be expanded to the identification of
early stage second primary tumours in patients with
synchronous pulmonary lesions.
Currently, elaborate and invasive diagnostic procedures
are required for the diagnosis of second primary cancer.
FDG PET may be a cost-effective modality as it may
identify second primary lung tumours at an early and
curable stage (stage I–IIIA) in a non-invasive way. Large
differences in SUVs between lung tumours in a single
patient should urge physicians to consider a second primary
lung cancer rather than metastatic disease, resulting in
fewer patients wrongfully being withheld a curative
treatment. Since our study also included patients with
second primary cancer of the colorectum and head and
neck, FDG PET might also be useful in patients with
synchronous cancers of other organs in whom a diagnosis
of metastasis or second primary cancer has yet to be made.
The population studied was carefully defined by strin-
gent inclusion criteria. By including only those patients for
whom sufficient data for a definite diagnosis of second
primary cancer were available, the validity of this study was
strengthened. Additionally, conditions between the patient
groups studied were equalized as much as possible by
choosing one reconstruction method for all PET images,
since this is known to affect the SUV [37].
Patient no. Location
tumour 1
SUVmax
tumour 1
Location
tumour 2
SUVmax
tumour 2
ΔSUV
a ΔSUV%
b
1 Lung, RUL 4.50 Cecum 7.70 3.20 42
2 Lung, RLL 8.00 Lung, LLL 3.00 5.00 63
3 Lung, RML 20.7 Lung, RLL 5.00 15.7 76
4 Lung, RUL 10.3 Lung, LUL 8.40 1.90 18
5 Rectum 16.3 Lung, RUL 4.83 11.47 70
6 Colon 9.90 Lung, LLL 2.40 7.50 76
7 Lung, LUL 8.70 Lung, LLL 7.10 1.60 18
8 Soft palate 2.70 Lung, LUL 17.6 14.9 85
9 Lung, LUL 13.4 Lung, RML 6.70 6.70 50
10 Right oro/hypopharynx 18.0 Lung, LLL 5.20 12.8 71
11 Colon 19.4 Lung, LUL 5.70 13.7 71
12 Left oropharynx 23.4 Lung, RUL 7.60 15.8 68
13 Larynx 3.90 Lung, RLL 4.80 0.90 19
14 Lung, LUL 12.12 Lung, RLL 3.54 8.58 71
15 Colon 5.40 Lung, RUL 11.1 5.70 51
16 Left distal main bronchus 13.5 Lung, RUL 1.70 11.8 87
Mean ± SD 8.58±5.24 58±23
Table 3 Individual results of
second primary group
SUVmax maximum standardized
uptake value, RUL right upper
lobe, RLL right lower lobe, RML
right middle lobe, LUL left
upper lobe, LLL left lower lobe,
SD standard deviation of the
mean
aThe absolute difference
between the SUVmax of
tumour 1 and SUVmax
of tumour 2
bThe relative difference
between the SUVmax of
tumour 1 and the SUVmax
of tumour 2, expressed in
percentages of the
highest SUVmax
Fig. 5 ROC curve and corresponding AUC statistics for the ΔSUV.
For the optimal cut-off of ΔSUV=41%, both the sensitivity and
specificity are 81%
2044 Eur J Nucl Med Mol Imaging (2010) 37:2037–2047Several limitations to this study should be noted. First,
this study has a small sample size. Because of the
retrospective nature of the study, TP53 mutation analysis
was missing in many patients with histologically identi-
cal lesions and suspicion of a second primary tumour.
After exclusion of patients with missing digital PET data
and lesions prone to partial volume effects, only one
patient in whom TP53 analysis was performed was left
for inclusion.
Second, diagnosis was made without histological confir-
mation in most cases of metastatic disease. In these
patients, histopathology of the metastatic lesion was
lacking, because the clinical presence of multiple lesions
in a pattern typical for metastatic spread was considered
sufficient for diagnosis of metastatic disease. If this study
had been prospectively conducted, however, tissue for
immunohistochemical and mutation analyses could have
been sampled for all tumours, thereby assuring validity of
diagnoses of both patient groups studied.
Full kinetic analysis of the metabolic rate of FDG has
several advantages over the use of SUVs [38]. However,
dynamic scans are required for kinetic analysis, which are
not readily available in clinical settings [34]. Therefore, the
SUV is the most commonly used measure to quantify
tumour glucose metabolism on static PET images and its
use is further supported by studies showing high reproduc-
ibility [39, 40].
To secure comparability of ΔSUVs between patients, only
patients with FDG PET images reconstructed at the same
resolution (2 iterations and 8 subsets) were included.
However, reconstruction with a higher amount of iterations
may be preferred to obtain sufficient convergence, which
makes the SUV less dependent on surrounding activity [37].
Also, the SUV was normalized to body weight and not to the
more preferable body surface area or plasma glucose values
[41]. However, these limitations affect the absolute values of
SUVs and do not have a large impact on intra-individual
differences in SUVs (ΔSUVs), as used in this study.
Conclusions
The results ofthisstudysuggest thatmeasurement ofthe SUV
using FDG PET images can be useful in differentiating
metastatic disease from second primary cancer in patients
presenting with synchronous pulmonary lesions. This
non-invasive technique, which is standardly available in
pre-surgically staged lung cancer patients, may increase
cost-effectiveness due to less cumbersome diagnostic proce-
dures and more efficient identification of potentially curable
second primary cancer patients. However, larger and prospec-
tively conducted studies are warranted to confirm the
consistency of these results and to test the accuracy of the
ΔSUVat the cut-off value proposed in this study.
Table 4 Individual data of CT characteristics
Patient no. Tumour 1 Tumour 2 ΔSUV%
Metastasis
group
1 Metastasis
a Metastasis 8
2 Metastasis Unsure
b 32
3 Metastasis Unsure 12
4 Metastasis Unsure 14
5 Metastasis Unsure 26
6 Metastasis Metastasis 29
7 Metastasis Unsure 51
8 Primary
c Unsure 12
9 Metastasis Unsure 2
10 Metastasis Metastasis 29
11 Metastasis Metastasis 75
12 Unsure Unsure 3
13 Metastasis Unsure 21
14 Primary Metastasis 43
15 Metastasis Unsure 41
16 Metastasis Unsure 77
17 Metastasis Unsure 26
18 Metastasis Unsure 24
19 Metastasis Unsure 16
20 Metastasis Unsure 16
21 Metastasis Metastasis 31
Second
primary
group
1 Primary Unsure 42
2 Primary Unsure 63
3 Metastasis Unsure 76
4 Primary Primary 18
5 Unsure Primary 70
6 Unsure Primary 76
7 Primary Primary 18
8 Unsure Primary 85
9 Primary Primary 50
10 Unsure Metastasis 71
11 Unsure Unsure 71
12 Unsure Metastasis 68
13 Unsure Primary 19
14 Primary Primary 71
15 Unsure Primary 51
16 Primary Primary 87
ΔSUV% the relative difference between the SUVmax of tumour 1 and
the SUVmax of tumour 2, expressed in percentages of the highest
SUVmax
aTumours were considered metastases if the following features were
present: round lesions, sharp borders and homogeneous
bBased on CT characteristics, no definite diagnosis of a primary tumour or
metastasis could be made
cTumours were considered primary tumours if the following features were
present: speculation, cavitation, irregular margins, pleural or bronchial
traction
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